IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 135 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 » Next article
 » Previous article 
 » Table of Contents
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (66 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

In This Article
 »  References
 »  Article Figures

 Article Access Statistics
    PDF Downloaded1572    
    Comments [Add]    
    Cited by others 15    

Recommend this journal


Year : 2009  |  Volume : 41  |  Issue : 4  |  Page : 197-198

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes

Department of Pharmacology, AIMSR, Bhatinda, India

Date of Web Publication26-Sep-2009

Correspondence Address:
Rajiv Mahajan
Department of Pharmacology, AIMSR, Bhatinda
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0253-7613.56070

Rights and Permissions

How to cite this article:
Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol 2009;41:197-8

How to cite this URL:
Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J Pharmacol [serial online] 2009 [cited 2023 Jun 10];41:197-8. Available from: https://www.ijp-online.com/text.asp?2009/41/4/197/56070

The food and drug administration (FDA), on May 5, approved bromocriptine mesylate 0.8-mg tablets as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. This drug has been developed by Vero Science Inc, under the trade name Cycloset. The product is a quick-release formulation of bromocriptine, a centrally-acting dopamine D 2 receptor agonist. [1] Bromocriptine is otherwise approved for the treatment of hyperprolactinemia-associated dysfunctions, acromegaly and Parkinson disease. [2] The idea of using bromocriptine for the treatment of type-2 diabetes came while studying the metabolism of migrating birds; that they develop seasonal insulin resistance and dopamine plays a role in it. [3] The results of phase 3b trial, conducted in response to a letter from FDA requesting additional data on bromocriptine cardiovascular safety, were declared in the second quarter of 2007 [2] and finally approved recently.

Preclinical data suggest that decreased hypothalamic dopaminergic tone may be involved in the pathogenesis of insulin resistance. The normal circadian cycle that results in a leaner body in the summer and heavier body in winter is disrupted in humans because of abundant caloric intake year-round resulting in the absence of a lean phase. Stimulation of the hypothalamus promotes the release of several hormones that respond to the traditional shift in caloric intake and storage. Quick-release bromocriptine (D 2 agonist), given once in the morning, stimulates the hypothalamus to release cortisol, growth hormone, and prolactin, allowing a reset of the circadian clock permanently stuck in a winter rhythm. [2] This means there occurs resetting of abnormally elevated hypothalamic drive for increased plasma glucose, triglyceride and free fatty acid levels in fasting and postprandial states in insulin-resistant patients [1] [Figure 1].

Bromocriptine mesylate is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. It may be used as monotherapy or as adjunctive therapy to metformin/sulfonylurea and single or dual oral hypoglycemic agent therapies. It should not be used to treat type-1 diabetes or diabetic ketoacidosis. There is limited efficacy data in combination with thiazolidinediones and efficacy has not been confirmed in combination with insulin. [4]

Bromocriptine is the first drug for treatment of diabetes to be approved under the FDA's new guidelines which require clinical trials to demonstrate no increased cardiovascular risk. [1] In a 52-week, double-blind, placebo-controlled safety trial (n = 3070), treatment with quick-release formulation of bromocriptine reduces the incidence of diabetic cardiovascular complications in patients with type-2 diabetes and improves glycemic control in those patients who did not achieve HbA 1c of less than 7.5% with metformin plus a sulfonylurea. The incidence of the composite cardiovascular end point of myocardial infarction (MI), stroke, coronary revascularization, and hospitalization for congestive heart failure (CHF) or unstable angina was 1.5% among patients receiving bromocriptine and three percent among patients receiving placebo.[2]

The recommended starting dose of bromocriptine is 0.8 mg daily and increased in 0.8 mg increments weekly until the target range (1.6 - 4.8 mg) or till maximal tolerance is reached. Doses should be administered once daily within two hours of waking in the morning and with food to reduce the risk for gastrointestinal adverse effects such as nausea. [1] Studies suggest that one morning dose helped lower the usual post-meal blood sugar rise at breakfast, lunch and dinner. Over six months, 35% of drug users reached recommended average blood sugar levels compared with 10 per cent of diabetics given placebo. [3]

The drug is contraindicated in patients with known hypersensitivity to bromocriptine or ergot-related drugs. It is also contraindicated in patients with syncopal migraine. Bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. Loss of consciousness during migraine may reflect dopamine receptor hypersensitivity. Bromocriptine is a dopamine receptor agonist, and may, therefore, potentiate the risk for syncope in these patients. [4] It is also contraindicated in nursing women. Bromocriptine may inhibit lactation. There are postmarketing reports of stroke in these patients although causality has not been proven. [3]

The most common adverse events associated with bromocriptine mesylate are nausea, fatigue, dizziness, vomiting and headache. Clinical trial data reveal that bromocriptine mesylate at doses up to 4.8 mg per day was not associated with a different rate of all-cause adverse events compared with placebo. The incidence of hypoglycemia was 6.9% among bromocriptine mesylate-treated patients compared with 5.3% of patients receiving placebo. [5]

The FDA warns that bromocriptine can cause orthostatic hypotension and syncope, particularly on initiation of therapy and dose escalation. Caution is advised when treating patients who are receiving antihypertensive therapy; orthostatic vital signs should be evaluated at baseline and periodically thereafter. [1]

Several oral hypoglycemic agents are already available for type-2 diabetic patients to normalize plasma glucose concentration. However, they have not had complete and sustained success. Some benefits of quick release bromocriptine mesylate therapy include:

  • Resetting of circadian rhythm, a novel mechanism of action very different from currently used antidiabetic drugs
  • Use with other antidiabetic agents
  • Ease of a single morning daily dose
  • Lower incidence of MI, stroke, and vascular events unlike other antidiabetic agents.
Due to these beneficial effects bromocriptine mesylate may prove to be a revolution in the field of treatment of type-2 diabetes.

 » References Top

1.Waknine Y. FDA approvals: Fanapt and cycloset. Medscape CME 2009. Available from: http://www.cme.medscape.com/viewarticle/702793. [cited 2009 May 24]  Back to cited text no. 1      
2.Gaziano JM. Quick-release bromocriptine has favorable cardiovascular safety profile. Proceedings of the 67th Annual Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago, Illinois, USA. [press release] Chicago: PRNewswire; 2007 Jun 23.  Back to cited text no. 2      
3.Hennessy T. Old Parkinson′s drug tweaked into diabetes treatment. The Associated Press; 2009 May 7.  Back to cited text no. 3      
4.U.S. Food and Drug Administration. Cycloset Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf. [cited 2009 May 21]  Back to cited text no. 4      
5.Bromocriptine mesylate approved for treatment of type 2 diabetes. Endocrinetoday 2009 In press.  Back to cited text no. 5      


  [Figure 1]

This article has been cited by
1 Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis
Beyene Dereje, Aschalew Nardos
Journal of Diabetes & Metabolic Disorders. 2023;
[Pubmed] | [DOI]
2 Perioperative Management of Diabetes in Patients Undergoing Bariatric and Metabolic Surgery: A Narrative Review and The Cleveland Clinic Practical Recommendations
Oscar L. Morey-Vargas, Ali Aminian, Karen Steckner, Keren Zhou, Sangeeta Kashyap, Derrick Cetin, Kevin M. Pantalone, Christopher Daigle, Marcio L. Griebeler, W. Scott Butsch, Robert Zimmerman, Matthew Kroh, Hussein F. Saadi, Danielle Diemer CNP, Bartolome Burguera, Raul J. Rosenthal, M. Cecilia Lansang
Surgery for Obesity and Related Diseases. 2022;
[Pubmed] | [DOI]
3 Bromocriptine therapy: Review of mechanism of action, safety and tolerability
Faiza Naz, Abdul Malik, Muhammad Riaz, Qaisar Mahmood, Malik Hassan Mehmood, Ghulam Rasool, Zahed Mahmood, Mazhar Abbas
Clinical and Experimental Pharmacology and Physiology. 2022;
[Pubmed] | [DOI]
4 Inhibition of NLRP3 and Golph3 ameliorates diabetes-induced neuroinflammation in vitro and in vivo
Yuan Li, Haifeng Zhang, Weihong Long, Menghan Gao, Weiying Guo, Lu Yu
Aging. 2022;
[Pubmed] | [DOI]
5 Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
Md. Tanvir Kabir, Jannatul Ferdous Mitu, Raushanara Akter, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed Al-Harrasi, Saurabh Bhatia, Md. Sohanur Rahman, Fouad Damiri, Mohammed Berrada, Md. Habibur Rahman
Environmental Science and Pollution Research. 2022;
[Pubmed] | [DOI]
6 Circadian rhythms and pancreas physiology: A review
Karl Chan, F. Susan Wong, James Alexander Pearson
Frontiers in Endocrinology. 2022; 13
[Pubmed] | [DOI]
7 Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats
Mohammed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi
Current Therapeutic Research. 2021; 95: 100647
[Pubmed] | [DOI]
8 Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel
S. Kalra, S. Ghosh, A.K. Das, T. Nair, S. Bajaj, G. Priya, R.N. Mehrotra, S. Das, P. Shah, V. Deshmukh, M. Chawla, D. Sanyal, S. Chandrasekaran, D. Khandelwal, A. Joshi, F. Eliana, H. Permana, M.D. Fariduddin, P.K. Shrestha, D. Shrestha, S. Kahandawa, M. Sumanathilaka, A. Shaheed, A.A. Rahim, A. Orabi, A. Al-ani, W. Hussein, D. Kumar, K. Shaikh
Indian Heart Journal. 2020; 72(1): 7
[Pubmed] | [DOI]
9 Influence of Bromocriptine Plus Metformin Treatment on Glycaemia and Blood Pressure in Patients with Type 2 Diabetes Mellitus
Alfredo Briones-Aranda, Javier Ramírez-Carballo, Bernardo Alfredo Romero Gómez, Victor Manuel Vega Villa, Manuela Castellanos Pérez, Esmeralda Garcia Parra, Hugo Roberto Santeliz-Montero
Romanian Journal of Diabetes Nutrition and Metabolic Diseases. 2018; 25(1): 59
[Pubmed] | [DOI]
10 Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases
Alexander O Shpakov, Kira V Derkach, Lev M Berstein
Future Science OA. 2015; 1(3)
[Pubmed] | [DOI]
11 Antihyperglycemic, Antihyperlipidemic and Cardioprotective Profile of Bromocriptine, Glibenclamide and Metformin Combination in Dexamethasone-induced Hyperglycemic Rats
Adejuwon Adewale Adeneye,Joseph Abayomi Olagunju
Pharmacologia. 2012; 3(12): 665
[Pubmed] | [DOI]
12 Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study
European Journal of Pharmaceutics and Biopharmaceutics. 2011;
[VIEW] | [DOI]
13 Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus
Kerr, J.L., Timpe, E.M., Petkewicz, K.A.
Annals of Pharmacotherapy. 2010; 44(11): 1777-1785
14 A systematic account of pathogenesis, diagnosis and pharmacotherapy of metabolic syndrome: Things we need to know
Mahajan, R., Gupta, K., Kapoor, V.
International Journal of Pharmacology. 2010; 6(4): 430-437
15 A Systematic Account of Pathogenesis, Diagnosis and Pharmacotherapy of Metabolic Syndrome: Things We Need to Know
R. Mahajan, K. Gupta, V. Kapoor
International Journal of Pharmacology. 2010; 6(4): 338
[VIEW] | [DOI]


Print this article  Email this article


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow